EP Vantage’s latest report, Biggest Launches 2014, reveals that although the past two years have brought a surge of R&D productivity, driving investor confidence and increasing market performance, 2014 looks set to tell a different tale.
According to the report only three drugs slated to launch this year will achieve blockbuster status by 2018.
The industry's move towards so-called "nichebuster" drugs could help explain the switch from blockbuster drug development, as the orphan indication delivers greater returns on investment. Yet, billion-dollar drugs remain an indicator of the sector's productivity and their absence in the 2014 launch class is an indicator to be watched closely.
Among the report’s key findings:
To download your complimentary copy of this report, please confirm your details on the opposite form.